Versant Capital Management’s Heron Therapeutics HRTX Stock Holding History

Versant Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-16	Closed	–	–	1557
2020 Q4	$0	Buy	+16	New	+$278	﹤0.01%	1420
2020 Q1	–	Sell	-39	Closed	–	–	1465
2019 Q4	$0	Hold	39	–	–	﹤0.01%	1449
2019 Q3	$0	Buy	+39	New	+$718	﹤0.01%	1456
2019 Q2	–	Sell	-17	Closed	–	–	1528
2019 Q1	$0	Buy	+17	New	+$445	﹤0.01%	1636

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Versant Capital Management's HRTX Position: Q1 2021 in Review

Versant Capital Management sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 16 shares.

Versant Capital Management first reported a position in HRTX in Q1 2019 and held it in 4 quarters. The position peaked at $0 in Q4 2020. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Versant Capital Management reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Versant Capital Management sold 16 Heron Therapeutics shares in Q1 2021.
Versant Capital Management first reported a position in Heron Therapeutics in Q1 2019 and held it in 4 quarters.
Versant Capital Management's Heron Therapeutics position peaked at $0 in Q4 2020.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Versant Capital Management's 13F filing for Q1 2021, filed 27 Apr 2021.